Scholarlink

<p>Polycystic ovary syndrome (PCOS) is the most common form of endocrinopathy in premenopausal women. In addition to reproductive impairments, PCOS is also associated with an increased risk for cardiometabolic sequelae. These include not only the presence of an insulin resistance and classical cardiovascular risks, such as type&#xa0;2 diabetes, obesity, dyslipidemia, and arterial hypertension but also the early manifestation of cardiovascular events and increased cardiovascular mortality. As a consequence, two key tasks emerge for specialists in internal medicine and diabetologists in the care of PCOS: firstly, a&#xa0;structured education of affected women about the specific cardiometabolic risks associated with PCOS is essential to enable self-care. Secondly, the early initiation of a&#xa0;systematic screening, monitoring and individual risk stratification of women affected by PCOS is essential to address the cardiometabolic risks and diseases identified as a consequence and for a timely initiation of treatment and to exploit the potential for prevention. Raising awareness on the systemic nature of this frequently underestimated chronic condition and an interdisciplinary management strategy involving diverse medical disciplines could help to decisively improve the cardiometabolic health of women affected. The recommendations of the upcoming national guidelines on the diagnostics and treatment of PCOS will support the implementation of such a&#xa0;PCOS treatment strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Polyzystisches Ovarsyndrom als geschlechtsspezifisches kardiometabolisches Risiko

  • 期刊论文

  • 发表日期：

    2025年7月11日

查看全文
  • Young Hee Lee-Barkey,
  • Bernd Stratmann,
  • Tatjana Opacic,
  • Jasmin M. Klose,
  • Susanne Reger-Tan

摘要

Polycystic ovary syndrome (PCOS) is the most common form of endocrinopathy in premenopausal women. In addition to reproductive impairments, PCOS is also associated with an increased risk for cardiometabolic sequelae. These include not only the presence of an insulin resistance and classical cardiovascular risks, such as type 2 diabetes, obesity, dyslipidemia, and arterial hypertension but also the early manifestation of cardiovascular events and increased cardiovascular mortality. As a consequence, two key tasks emerge for specialists in internal medicine and diabetologists in the care of PCOS: firstly, a structured education of affected women about the specific cardiometabolic risks associated with PCOS is essential to enable self-care. Secondly, the early initiation of a systematic screening, monitoring and individual risk stratification of women affected by PCOS is essential to address the cardiometabolic risks and diseases identified as a consequence and for a timely initiation of treatment and to exploit the potential for prevention. Raising awareness on the systemic nature of this frequently underestimated chronic condition and an interdisciplinary management strategy involving diverse medical disciplines could help to decisively improve the cardiometabolic health of women affected. The recommendations of the upcoming national guidelines on the diagnostics and treatment of PCOS will support the implementation of such a PCOS treatment strategy.